Ivan Waissbluth, Director – Business Development

Ivan brings over 8 years of early stage drug development and commercialization experience to CCAB’s Business Development Division. Before joining CCAB, Ivan was the CEO of ScarX Therapeutics, a preclinical stage biotechnology company focused on developing a novel anti-fibrotic agent, where he was responsible for all aspects of the company’s corporate and R&D strategy and was successful in securing capital necessary to complete preclinical studies and prepare the initiation of Phase I/II clinical studies.

Ivan has previously held roles at MaRS Innovation (MI), the Centre for Drug Research and Development (CDRD), and at the University of British Columbia technology transfer office. Ivan also has experience performing investment diligence while working at the life science venture capital company, Burrill & Co.

Ivan holds a PhD in Experimental Medicine from the University of British Columbia.

Email: Ivan.waissbluth@ccabcanada.com

Phone: 647-715-2306